The US Food and Drug Administration (FDA) just green-lighted Filament Health Corporation, a clinical-stage company in the natural psychedelic medicine development business, to do a study on the effects of certain psychedelic drugs. Filament has already created around 70 strains of psychedelic mushrooms to be used for research, and they were able to raise a cool $2.5 million to continue studying the use of psychedelics through stabilized formulas. These would offer patients the benefits of better bioavailability, consistency, and a quicker onset as well as a reduction in side effects.
The Dispensary Fulton offering huge discounts on top brands all month long. The post Save…
Republicans seek to put Ohioans back in jail for conduct voters already approved. The post…
The proposal to exclude medical marijuana from workers’ compensation coverage in California raises important concerns…
ILGM is hitting the road in their revamped Airstream Bambi for the Home Grow Tour…
Meet the music and cannabis pioneer behind the Upper East Side's hottest new dispensary. The…
Let's dive into how this iconic marijuana mecca rose to prominence, flourished during the golden…